Evaluation of the BD Phoenix CPO Detect Test for the detection of carbapenemase-producing Enterobacterales
Abstract
Aims: This study aimed to evaluate the performance of the BD Phoenix CPO Detect Test (BD Diagnostic Systems) for the detection and classification of carbapenemase-mediated carbapenem resistance. Methods: A total of 447 Enterobacterales strains were included in the study. All strains were tested with the BD Phoenix CPO Detect Test and the modified carbapenem inactivation method. Results: Carbapenemase production was detected in 157 of 159 carbapenemase producers, including 95.7% of class B and 99.2% of class D isolates using the BD Phoenix CPO Detect Test. BD Phoenix CPO Detect has a sensitivity of 98.7% and a specificity of 95.5% in detecting carbapenemase production. Conclusion: The classification of OXA-48 and class B carbapenemases, the most common carbapenemases circulating in Turkey, was highly accurate.
Plain language summary
Enterobacterales are a type of bacteria that usually live harmlessly in the gut of humans. However, if the bacteria get access to the bladder or bloodstream, they can cause infection. Carbapenemase-producing Enterobacterales (CPE) are a type of bacteria that can cause carbapenem antibiotic-resistant infections, a group of powerful antibiotics. The rapid spread of CPE will pose an increasing threat to public health and medical treatment practices; therefore, rapid detection of CPE is crucial. This study assessed the performance of the BD Phoenix CPO Detect Test for the detection of carbapenemase-producing Enterobacterales. The BD Phoenix CPO Detect Test offers both the detection of carbapenemase production and antimicrobial susceptibility testing simultaneously and can be clinically useful for determining possible treatment options.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Antibacterial agents. In: Manual of Clinical Microbiology (11th Edition). Jorgensen JHPfaller MACarroll KC (Eds). ASM Press, DC, USA, 1171–1211 (2015).
- 2. Carbapenemase-producing organisms: a global scourge. Clin. Infect. Dis. 66, 1290–1297 (2018).
- 3. Clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae among adult inpatients in Singapore. Clin. Infect. Dis. 64(Suppl. 2), S68–S75 (2017).
- 4. . Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in south and southeast Asia. Clin. Microbiol. Rev. 30(1), 1–22 (2017).
- 5. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165, 1430–1435 (2005).
- 6. . The spread of carbapenemase-producing bacteria in Africa: a systematic review. J. Antimicrob. Chemother. 70, 23–40 (2015).
- 7. European Committee on Antimicrobial Susceptibility Testing. EUCAST Guidelines for Detection of Resistance Mechanisms and Specific Resistances of Clinical and/or Epidemiological Importance (2017). https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf
- 8. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother. 56, 2108–2113 (2012).
- 9. . High-stringency evaluation of the automated BD Phoenix CPO Detect and Rapidec Carba NP tests for detection and classification of carbapenemases. J. Clin. Microbiol. 55(12), 3437–3443 (2017). •• This study covers the majority of carbapenemases that may be encountered clinically and highly challenging carbapenemase-negative isolates.
- 10. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin. Microbiol. Infect. 17, 1798–1803 (2011).
- 11. Modified carbapenem inactivation method for phenotypic detection of carbapenemase production among Enterobacteriaceae. J. Clin. Microbiol. 55, 2321–2333 (2017).
- 12. . Investigation of carbapenem resistance and the first identification of Klebsiella pneumoniae carbapenemase (KPC) enzyme among Escherichia coli isolates in Turkey: a prospective study. Travel. Med. Infect. Dis. 14, 572–576 (2016).
- 13. . Diagnostic accuracy of BD Phoenix CPO Detect for carbapenemase production in 190 Enterobacteriaceae isolates. J. Clin. Microbiol. 56(12), e01043–18 (2018). • The accuracy of CPO Detect for carbapenemase-producing Enterobacterales with IMI-1 proved to be less reliable.
- 14. . Evaluation of BD Phoenix CPO Detect assay for detection of carbapenemase producing organisms in clinical samples in Singapore. Open. Forum. Infect. Dis. 5(Suppl. 1), S604–S605 (2018).
- 15. . Evaluation of the automated BD Phoenix CPO Detect panel in combination with the β-CARBA assay for detection and classification of carbapenemase-producing Enterobacterales. J. Microbiol. Methods 156, 29–33 (2019).
- 16. Performance of the BD Phoenix CPO Detect assay for detection and classification of carbapenemase-producing organisms. Eur. J. Clin. Microbiol. Infect. Dis. 40, 979–985 (2021).
- 17. . Evaluation of the BD Phoenix CPO Detect Test for the detection of carbapenemase producers. Clin. Microbiol. Infect. 26, 644.e9–644.e15 (2020).
- 18. Multicenter evaluation of the BD Phoenix CPO Detect Test for detection and classification of carbapenemase-producing organisms in clinical isolates. J. Clin. Microbiol. 58(5), e01752–19 (2020).
- 19. . Evaluation of the automated BD Phoenix CPO Detect Test for detection and classification of carbapenemases in Gram negatives. Diagn. Microbiol. Infect. Dis. 96, 114911 (2020).
- 20. Performance evaluation of diagnostic assays for detection and classification of carbapenemase-producing organisms. Antibiotics 10, 1457 (2021).
- 21. Evaluation of the BD Phoenix CPO Detect panel for prediction of Ambler class carbapenemases. Sci. Rep. 11, 13150 (2021). •• The multicenter study evaluating the performance of the CPO Detect against 1222 Klebsiella pneumoniae isolates from 26 European countries.
